ABSTRACT
Proteomic techniques now measure thousands of circulating proteins at population scale, driving a surge in biomarker studies and biological clocks. However, their potential impact, generalisability, and biological relevance is hard to assess without understanding the origins and role of the thousands of proteins implicated in these studies. Here, we provide a data-driven identification of the foundations of protein variation that underly their links to ageing and diseases, differ between sexes and ancestries, and help guide protein biomarker and drug target discovery. We use machine learning to systematically identify and quantify the foundations of plasma levels of ∼3,000 protein targets among 43,240 participants of the UK Biobank. Out of >1,700 participant and sample characteristics, we identify a median of 19 factors (range: 1-36) that jointly explained an average of 23.7% (max. 79.9%) of the variance in plasma levels across protein targets. Proteins segregated into distinct clusters according to their explanatory factors, with modifiable characteristics explaining more variance compared to genetic variation (13.3% vs 9.8%). We identify proteins for which the factors underlying their variation differed by sex (n=1414 proteins) or across ancestries (n=86 proteins). We establish a knowledge graph that integrates our findings with genetic studies and drug characteristics to guide identification of potential markers of target engagement. We demonstrate the value of our resource 1) by identifying disease-specific biomarkers, like matrix metalloproteinase 12 for abdominal aortic aneurysm, and 2) by developing a framework for phenotype enrichment of protein signatures from independent studies to identify underlying sources of variation. All results are explorable via an interactive web portal (https://omicscience.org/apps/prot_foundation) and can be readily integrated into ongoing studies using an associated R package.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the DZHK (German Centre for Cardiovascular Research) and the BMBF (German Ministry of Education and Research) to C.L. (Grant Number: 81X2100281). Co-funded by the European Union (ERC, GenDrug, 101116072) to M.P.. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. This work was supported by the de.NBI Cloud within the German Network for Bioinformatics Infrastructure (de.NBI) funded by the German Federal Ministry of Education and Research (BMBF) (031A532B, 031A533A, 031A533B, 031A534A, 031A535A, 031A537A, 031A537B, 031A537C, 031A537D, 031A538A).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the UKB study was obtained from the North West Centre for Research Ethics Committee as a Research tissue biobank (REC reference 11/NW/0382)(40) and all participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos